On Monday, Take-Two Interactive Software, Inc. (NASDAQ:TTWO)’s shares declined -24.20% to $-1.98.
Take-Two Interactive Software, Inc. (TTWO) stated strong revenues and better-than-predictable Non-GAAP earnings for its fourth quarter and fiscal year 2015, ended March 31, 2015, and offered its initial financial outlook for its first quarter and fiscal year 2016. In addition, the Company declared that its Board of Directors has approved an enhance to its share repurchase authorization up to an aggregate of 10 million shares of Take-Two’s common stock.
Fiscal Fourth Quarter 2015
GAAP Financial Results
For fiscal fourth quarter 2015, GAAP net revenue grew 54% to $300.1 million, as contrast to $195.2 million for fiscal fourth quarter 2014. GAAP net loss was $242.8 million, or $2.99 per diluted share, as contrast to $30.8 million, or $0.40 per diluted share, for the year-ago period. GAAP results for fiscal fourth quarter 2015 reflect the deferral of net revenue and cost of goods sold related to sell-in of certain titles during the quarter.
During fiscal fourth quarter 2015, the Company’s cash and short-term investments balance raised to $1.098 billion as of March 31, 2015, up from $976.6 million as of December 31, 2014.
Take-Two Interactive Software, Inc. develops, publishes, and markets interactive entertainment for consumers worldwide. The company offers its products under the Rockstar Games and 2K labels. It develops and publishes action/adventure products under the Grand Theft Auto, Max Payne, Midnight Club, and Red Dead names through developing sequels, offering downloadable episodes and content, and releasing titles for smartphones and tablets.
Diana Shipping Inc. (NYSE:DSX)’s shares dropped -3.87% to $6.95.
Diana Shipping Inc. (DSX) stated a net loss of $10.8 million and net loss attributed to common stockholders of $12.2 million for the first quarter of 2015, contrast to net loss of $6.0 million and net loss attributed to common stockholders of $6.8 million stated in the first quarter of 2014.
Time charter revenues were $42.0 million for the first quarter of 2015, contrast to $41.1 million for the same period of 2014. The enhance in time charter revenues was mainly due to the enhance in ownership days resulting from the enlargement of our fleet and was partly offset by reduced time charter rates.
Share Repurchase Plan
As formerly declared, on May 23, 2014, the Company’s Board of Directors authorized a share repurchase plan, under which, during the first quarter of 2015, the Company repurchased and stepped down 413,804 shares for an aggregate cost of about $2.7 million.
Diana Shipping Inc. provides shipping transportation services. The company transports dry bulk cargoes, counting commodities, such as iron ore, coal, grain, and other materials in shipping routes worldwide. As of May 8, 2015, it operated a fleet of 40 dry bulk vessels, counting 2 Newcastlemax, 12 Capesize, 3 Post-Panamax, 3 Kamsarmax, and 20 Panamax vessels.
At the end of Monday’s trade, Extreme Networks, Inc (NASDAQ:EXTR)‘s shares dipped -3.38% to $2.57.
Extreme Networks, Inc (EXTR) released financial results for the third quarter of fiscal year 2015, ended March 31, 2015. GAAP revenue was $119.6 million and non-GAAP revenue was $120.4 million. GAAP net loss for the third fiscal quarter was $23.5 million, or $0.24 per share, and non-GAAP net loss was $7.9 million, or $0.08 per share.
Recent Key Events:
Extreme Networks appoints Board Chairman Ed Meyercord as its President and Chief Executive Officer effective April 19, 2015.
Extreme extends planned leadership and experience to R&D with the promotion of Eric Broockman to CTO and executive vice president of engineering adding to his current responsibility as CTO, a role he has served the past 14 months. Broockman holds numerous U.S. patents, is an active inventor, and was a National Science Foundation Fellow.
Extreme strengthens administration team with three new executive appointments, announcing the promotions of Bob Gault as executive vice president worldwide sales, channel and services, Eileen Brooker as executive vice president of global alliances and planned accounts, and Norman Rice as executive vice president of global marketing and corporate development. These executives have demonstrated an unwavering commitment to customers and a passion for the highest levels of service in the networking industry throughout their careers.
Extreme Networks wins Network Computing’s new product of the year award for Purview Application Analytics. Readers voted Extreme Networks’ Purview™ as the best new-to-market product, highlighting its differentiated capabilities that assist transform the network into a planned business asset. Purview has been deployed by a wide variety of organizations counting large universities, government agencies, healthcare organizations, and stadiums.
Extreme Networks, Inc., together with its auxiliaries, provides wired and wireless network infrastructure equipment, software, and services for enterprises, data centers, and service providers.
DURECT Corporation (NASDAQ:DRRX), ended its Monday’s trading session with -3.83% loss, and closed at $2.26.
DURECT Corporation (DRRX) declared that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT’s Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It may also play an important role in protecting against acute kidney injury (AKI) and other types of acute organ injury.
Description of Phase I Multiple-Ascending-Dose Study with DUR-928
This Phase 1 trial was a single-site, randomized, double-blinded, placebo-controlled, multiple-ascending-dose study to evaluate the safety, tolerability, and pharmacokinetics of DUR-928 when orally administered once daily for 5 successive days to healthy volunteers. The 20-subject study evaluated DUR-928 in 2 successive 10-subject cohorts, the first receiving DUR-928 at a lower dose and the second at a higher dose.
Following multiple dosing, DUR-928 was well-tolerated at both dose levels, with no clinically noteworthychanges in vital signs, laboratory values or ECG parameters, no severe or serious drug-related adverse events stated and no subjects withdrawing from the study. Peak plasma concentrations achieved were at least 100-fold higher than endogenous levels, no accumulation in plasma concentrations were observed with repeat dosing, and dose related enhances in plasma concentrations were observed with peak plasma concentration at about 2 – 6 hours after dosing.
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. It provides ALZET product line comprising osmotic pumps and accessories that are used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers, which are used as raw materials for pharmaceutical and medical device under the LACTEL brand.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
